# EDGAR Filing Document

**Accession Number:** 0000715446
**File Stem:** 0000000000-25-010013
**Filing Date:** 2025-9
**Character Count:** 2393
**Document Hash:** 830609284ed895cef4b5dca749fc9951
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010013.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0000000000-25-010013

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250916

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anixa Biosciences Inc
- **CENTRAL INDEX KEY:** 0000715446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 112622630
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290178

**BUSINESS ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118
- **BUSINESS PHONE:** 408-708-9808

**MAIL ADDRESS:**
- **STREET 1:** 3150 ALMADEN EXPRESSWAY, SUITE 250
- **CITY:** SAN JOSE
- **STATE:** CA
- **ZIP:** 95118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ITUS Corp
- **DATE OF NAME CHANGE:** 20140902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COPYTELE INC
- **DATE OF NAME CHANGE:** 19920703
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-013010

## Text-Extract

```

                                                           September 16, 2025

Amit Kumar, Ph.D.
Chairman and Chief Executive Officer
Anixa Biosciences Inc
3150 Almaden Expressway, Suite 250
San Jose, CA 95118

       Re: Anixa Biosciences Inc
           Registration Statement on Form S-3
           Filed September 10, 2025
           File No. 333-290178
Dear Amit Kumar Ph.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Matthew Bernstein, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._